NEW YORK (GenomeWeb) – Luminex reported strong quarterly financial results on Monday, but said it is delaying until further notice the start of clinical trials for Verigene 2, an automated multiplex instrument that the firm is developing for infectious disease testing.

Luminex acquired Verigene 2 when it acquired Nanosphere in 2016. When it did, the firm halted development of Aries 2, its own higher plex instrument, in favor of developing the Verigene 2 product, also called Atlas.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.